(May 29, 2020, 1:54 PM EDT) -- SAN DIEGO — A biopharmaceutical company and two of its senior executives misrepresented to investors that the company had discovered an antibody that would serve as a “cure” to the novel coronavirus in violation of federal securities laws even though the company’s collaborative partner disputed such claims, a shareholder argues in a May 26 securities class action filed in California federal court (Wasa Medical Holdings v. Sorrento Therapeutics Inc., et al., No. 20-966, S.D. Calif.)....